Heidi M. Schaefer

Heidi M. Schaefer

Auto-generated profile, based on publicly available information

Heidi M. Schaefer

Department of Medicine Division of Kidney and Pancreas Transplant Vanderbilt University Medical Center Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
ESEllen Shukhman
Ellen Shukhman
JHJulia Hunt
Julia Hunt
DLDianne LaPointe‐Rudow
Dianne LaPointe‐Rudow
DMDidier Mandelbrot
Didier Mandelbrot
RHRebecca E. Hays
Rebecca E. Hays
KLKrista L Lentine
Krista L Lentine

28 March 2024 in Clinical Transplantation
Verified
Journal Article
Open access
ACAlissar El Chediak
Alissar El Chediak
SSSaed Shawar
Saed Shawar
MFMohammad K. Fallahzadeh
Mohammad K. Fallahzadeh
RFRachel Forbes
Rachel Forbes
HSHeidi M. Schaefer
Heidi M. Schaefer
DSDavid Shaffer
David Shaffer
Introduction: Data on long‐term outcomes following A2/A2B to B kidney transplants since the 2014 kidney allocation system (KAS) changes are few. The primary aim of this study is to report our 7‐year experience with A2/A2B to B kidney transplants and to compare post‐transplant outcomes of A2/A2B to a concurrent group of B to B kidney transplants. Additionally, the study evaluates the impact of pre‐transplant anti‐A1 titers on survival outcomes in A2/A2B transplants.Methods: This retrospective, single‐center analysis included all adults who received A2/A2B to B deceased donor kidney transplants from December 2014 to June 2021 compared to B to B recipients. The effects of pre‐transplant IgM/IgG titers, stratified as ≤1:8 and ≥1:16, on death‐censored, rejection‐free, and overall graft survival were tested.Results: Fifty‐three A2/A2B and 114 B to B adults were included with a median follow‐up time of 32 months. Overall graft survival, patient survival, and rejection‐free graft survival did not differ between the two groups. There were no differences between the groups’ overall kidney function values (p > .80) or their temporal trajectories (time by group interaction p > .11). Unadjusted death‐censored graft survival was lower in A2/A2B to B compared to B recipients (p = .03), but the effect was not significant (p = .195) after adjusting for any readmissions (p = .96), rejection episodes (p < .001) or BK infection (p = .76). We did not detect an effect of pre‐transplant titer group on death‐censored (p = .59), rejection‐free (p = .61), or overall graft survival (p = .26)Conclusions: A2/A2B to B kidney transplants have comparable overall patient and graft survival, rejection‐free graft survival, and longitudinal renal function compared to B to B transplants at our center. Allograft survival outcomes were not significantly different between patients with low and high pre‐transplant anti‐A1 IgM/IgG titers.

22 May 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
RFRachel C. Forbes
Rachel C. Forbes
BCBeatrice P. Concepcion
Beatrice P. Concepcion
DCDeana Clapper
Deana Clapper
BDBernard J. DuBray
Bernard J. DuBray
SSSaed Shawar
Saed Shawar
KJKeith Johnson
Keith Johnson

19 December 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
LBLaura A. Binari
Laura A. Binari
PTPeter Thorne
Peter Thorne
SRScott A. Rega
Scott A. Rega
IFIrene D. Feurer
Irene D. Feurer
SSSaed Shawar
Saed Shawar
RFRachel C. Forbes
Rachel C. Forbes